Long-term Debt and Capital Lease Obligations

The following is a summary of indebtedness outstanding:



(In thousands)	2013			2012

Note agreement, 5.54%	$	30,608		$	45,045
Senior Notes, Series B, 6.42%	—			9,750
Capital lease obligations	135,216			141,344

Total debt and capital lease obligations	165,824			196,139
Less: current portion	(54,107		)	(59,582		)

Long-term debt and capital lease obligations	$	111,717		$	136,557

In November 2005, we completed a £65.0 million unsecured private placement of debt at 5.54% pursuant to a Note Agreement. The Note Agreement is payable in seven equal annual installments, which commenced November 2009. The proceeds were used to repay the outstanding amount under our credit facility and for general corporate purposes. The Note Agreement contains certain net worth and fixed charge coverage covenants and provides certain restrictions on our ability to borrow, incur liens, sell assets and pay dividends. We were in compliance with all covenants at the end of 2013.

In December 2002, we completed a $60.0 million unsecured private placement of debt pursuant to a Note Agreement. The Series A Senior Notes, with a $21.0 million principal amount at 5.57% were paid in full in 2008. The Series B Senior Notes, with a $39.0 million principal amount at 6.42%, were paid in full in 2013.

Our capital lease obligations are primarily related to the procurement of hardware and medical devices, and generally have a term of five years.

Minimum annual payments under existing capital lease obligations and maturities of indebtedness at the end of 2013 are as follows:



	Capital Lease Obligations
(In thousands)	Minimum Lease Payments		Less: Interest		Principal		Principal Amount of Indebtedness		Total

2014	$	42,353	$	3,550	$	38,803	$	15,304	$	54,107
2015	41,397		2,311		39,086		15,304		54,390
2016	37,461		1,089		36,372		—		36,372
2017	18,331		265		18,066		—		18,066
2018	2,912		23		2,889		—		2,889

Total	$	142,454	$	7,238	$	135,216	$	30,608	$	165,824

We maintain a $100.0 million multi-year revolving credit facility, which expires in February 2017. The facility provides an unsecured revolving line of credit for working capital purposes, along with a letter of credit facility. Interest is payable at a rate based on prime, LIBOR, or the U.S. federal funds rate, plus a spread that varies depending on the leverage ratios maintained. The agreement provides certain restrictions on our ability to borrow, incur liens, sell assets and pay dividends and contains certain cash flow and liquidity covenants. As of the end of 2013, we were in compliance with all debt covenants. As of the end of 2013, we had no outstanding borrowings under this agreement; however, we had $17.1 million of outstanding letters of credit, which reduced our available borrowing capacity to $82.9 million.